NYSE · GMAB
Healthcare · Biotechnology
$34.74
Up+$0.21 (+0.59%)
Updated Sep 20, 2026, 12:31 PM
SID Score
7.2/10
Composite research score
Smart Money
55/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
GMAB closed at $34.74 after 19 trading sessions, up 5.21% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $34.92 | $35.15 | $34.715 | $34.74 | 2.71M |
| Sep 17, 2026 | $34.28 | $34.77 | $34.22 | $34.535 | 2.7M |
| Sep 16, 2026 | $34.36 | $34.63 | $34.05 | $34.40 | 2.89M |
| Sep 15, 2026 | $32.34 | $34.185 | $32.34 | $34.15 | 3.09M |
| Sep 14, 2026 | $32.79 | $32.96 | $32.52 | $32.65 | 1.41M |
| Sep 11, 2026 | $32.45 | $32.70 | $32.27 | $32.47 | 1.39M |
| Sep 10, 2026 | $32.46 | $32.68 | $32.21 | $32.23 | 1.02M |
| Sep 9, 2026 | $33.47 | $33.75 | $32.98 | $33.04 | 2.13M |
| Sep 8, 2026 | $33.71 | $33.84 | $33.36 | $33.53 | 1.55M |
| Sep 4, 2026 | $33.96 | $34.19 | $33.545 | $33.60 | 1M |
| Sep 3, 2026 | $34.63 | $34.66 | $34.08 | $34.41 | 890.95K |
| Sep 2, 2026 | $34.04 | $34.50 | $33.74 | $34.215 | 2.08M |
| Sep 1, 2026 | $33.33 | $33.67 | $33.15 | $33.29 | 1.56M |
| Aug 31, 2026 | $32.76 | $33.26 | $32.5401 | $33.16 | 1.73M |
| Aug 28, 2026 | $33.78 | $33.9295 | $33.115 | $33.23 | 1.52M |
| Aug 27, 2026 | $33.91 | $34.165 | $33.67 | $34.10 | 1.87M |
| Aug 26, 2026 | $33.78 | $33.90 | $33.36 | $33.75 | 3.09M |
| Aug 25, 2026 | $33.81 | $34.4699 | $33.72 | $34.36 | 2.03M |
| Aug 24, 2026 | $32.82 | $33.32 | $32.74 | $33.02 | 3.25M |
The latest Smart Investors Daily articles mentioning GMAB.
GMAB research
Company profile and research snapshot.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Buy | — |
| Jul 12, 2026 | TD COWEN | Hold | — |
| Jul 12, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Jul 7, 2026 | DNB CARNEGIE | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Genmab A/S (GMAB) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsJan van de Winkel - Co-Founder,...
Benzinga · Sep 14, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $40 price target.
Yahoo · Sep 8, 2026
Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,409 shares at DKK 1,334.50,1,464 shares at DKK 1,362.50,20,270 shares at DKK 1,615.00, and1,868 shares at DK
Yahoo · Sep 8, 2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl Jacobsens Vej 30, 2500 Valby, Denmark. The notice for the Extraordinary General Meeting, including Appendix 1: Shareholder Letter, is attached. Shareholders are encouraged to visit Genmab’s website at Gen
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GMAB.
